CS-023 (
RO4908463, formerly
R-115685) is a novel
1beta-methylcarbapenem with 5-substituted pyrrolidin-3-ylthio groups, including an amidine moiety at the C-2 position. Its antibacterial activity was tested against 1,214 clinical isolates of 32 species and was compared with those of
imipenem,
meropenem,
ceftazidime,
ceftriaxone,
ampicillin,
amikacin, and
levofloxacin.
CS-023 exhibited a broad spectrum of activity against gram-positive and -negative aerobes and anaerobes, including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis,
penicillin-resistant Streptococcus pneumoniae (PRSP),
beta-lactamase-negative
ampicillin-resistant Haemophilus influenzae, and Pseudomonas aeruginosa.
CS-023 showed the most potent activity among the compounds tested against P. aeruginosa and MRSA, with MICs at which 90% of isolates tested were inhibited of 4 microg/ml and 8 microg/ml, respectively.
CS-023 was stable against hydrolysis by the
beta-lactamases from Enterobacter cloacae and Proteus vulgaris.
CS-023 also showed potent activity against extended-spectrum
beta-lactamase-producing Escherichia coli. The in vivo efficacy of
CS-023 was evaluated with a murine systemic
infection model induced by 13 strains of gram-positive and -negative pathogens and a lung
infection model induced by 2 strains of PRSP (serotypes 6 and 19). Against the systemic
infections with PRSP, MRSA, and P. aeruginosa and the lung
infections, the efficacy of
CS-023 was comparable to those of
imipenem/cilastatin and
vancomycin (tested against lung
infections only) and superior to those of
meropenem,
ceftriaxone, and
ceftazidime (tested against P. aeruginosa
infections only). These results suggest that
CS-023 has potential for the treatment of nosocomial
bacterial infections by gram-positive and -negative pathogens, including MRSA and P. aeruginosa.